Interleukin-22 Contributes to Blood–Brain Barrier Disruption via STAT3/VEGFA Activation in Escherichia coli Meningitis
ACS Infectious Diseases · 08.03.2024 · 10 (3) · 988-999
DOI: 10.1021/acsinfecdis.3c00668 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 06.02.2024. Verfasst von Ruicheng Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China. Hauptthemen laut MEDLINE: Meningitis, Escherichia coli, Escherichia coli Infections, Meningitis, Bacterial. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Agricultural Research System, National Key Research and Development Program of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Escherichia coli continues to be the predominant Gram-negative pathogen causing neonatal meningitis worldwide. Inflammatory mediators have been implicated in the pathogenesis of meningitis and are key therapeutic targets. The role of interleukin-22 (IL-22) in various diseases is diverse, with both protective and pathogenic effects. However, little is understood about the mechanisms underlying the damaging effects of IL-22 on the blood-brain barrier (BBB) in E. coli meningitis. We observed that meningitic E. coli infection induced IL-22 expression in the serum and brain of mice. The tight junction proteins (TJPs) components ZO-1, Occludin, and Claudin-5 were degraded in the mouse brain and human brain microvascular endothelial cells (hBMEC) following IL-22 administration. Moreover, the meningitic E. coli-caused increase in BBB permeability in wild-type mice was restored by knocking out IL-22. Mechanistically, IL-22 activated the STAT3-VEGFA signaling cascade in E. coli meningitis, thus eliciting the degradation of TJPs to induce BBB disruption. Our data indicated that IL-22 is an essential host accomplice during E. coli-caused BBB disruption and could be targeted for the therapy of bacterial meningitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China.
- Key Laboratory of Preventive Veterinary Medicine in Hubei Province, The Cooperative Innovation Center for Sustainable Pig Production, Wuhan 430070, China.
- Frontiers Science Center for Animal Breeding and Sustainable Production, Wuhan 430070, China.
- International Research Center for Animal Disease, Ministry of Science and Technology of the People's Republic of China, Wuhan 430070, China.
ORCID-Profile: Chen Tan, Xiangru Wang
Förderung
- China Agricultural Research System
- National Key Research and Development Program of China
- China Postdoctoral Science Foundation
- Natural Science Foundation of Hubei Province
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Yang, R., Chen, J., Qu, X., Liu, H., Wang, X., Tan, C., Chen, H., & Wang, X. (2024). Interleukin-22 Contributes to Blood–Brain Barrier Disruption via STAT3/VEGFA Activation in Escherichia coli Meningitis. ACS Infectious Diseases, 10(3), 988-999. https://doi.org/10.1021/acsinfecdis.3c00668
Vancouver
Yang R, Chen J, Qu X, Liu H, Wang X, Tan C, et al. Interleukin-22 Contributes to Blood–Brain Barrier Disruption via STAT3/VEGFA Activation in Escherichia coli Meningitis. ACS Infectious Diseases. 2024;10(3):988-999. doi:10.1021/acsinfecdis.3c00668
BibTeX
@article{Yang2024,
author = {Yang, Ruicheng and Chen, Jiaqi and Qu, Xinyi and Liu, Hulin and Wang, Xinyi and Tan, Chen and Chen, Huanchun and Wang, Xiangru},
title = {Interleukin-22 Contributes to Blood–Brain Barrier Disruption via STAT3/VEGFA Activation in Escherichia coli Meningitis},
journal = {ACS Infectious Diseases},
year = {2024},
volume = {10},
number = {3},
pages = {988--999},
doi = {10.1021/acsinfecdis.3c00668}
}
EUVIMED